Uppsala, Sweden, 4 April, 2007 - Biacore, now part of GE
Healthcare, announced today that Phoenix, Arizona, US will be the
venue for the second Developments in Protein Interaction Analysis
(DiPIA) conference on 6-9 May 2007. The event is organized by
Biacore and follows the highly successful DiPIA conference which
took place in Philadelphia, US in August 2005, attended by 300
delegates.
DiPIA 2007 offers participants an exciting opportunity for
exchange and discussion of all the latest developments in protein
interaction analysis. The event provides an outstanding forum for
presenting new concepts and advanced techniques in protein
interaction analysis, across the entire spectrum of modern
biological research. Measuring the interaction of biologically
active molecules plays a key role in modern biology, from research
through drug discovery to development and production.
DiPIA 2007 will comprise a series of workshops and presentations,
including education and scientific sessions, as well as roundtable
discussions and poster sessions. There will also be an Award for
Excellence and two Young Investigator poster awards.
The key topics to be covered at the Scientific Sessions are:
Infectious disease and immune recognition; Antibody and protein
therapeutics development; Small molecule drug discovery;
Functional protein networks and pathways; Beyond protein-protein
interactions; and Novel approaches to protein interaction
analysis.
Keynote speakers are from research and the pharmaceutical
industry, including: Professor Philip Andrews, Department of
Biological Chemistry at the University of Michigan Medical School,
who will give a presentation on ‘Determining the molecular
architecture of the zymogen secretory vesicle’.
DiPIA 2007 will be held at the Pointe Hilton Squaw Peak Resort in
Phoenix (
www.pointehilton.com).
For a full schedule and registration details visit:
www.biacore.com
- Ends –
About Biacore, part of GE Healthcare:
Biacore™ systems for label-free interaction analysis generate
unique data on molecular interactions, giving insights into
biological functions and disease mechanisms, and facilitating
efficient therapeutic development. Application areas include drug
discovery, general life science research, antibody
characterization, immunogenicity, biotherapeutic development and
manufacture. The company, also named Biacore, became part of GE
Healthcare in 2006. For more information, visit: www.biacore.com
About GE HEALTHCARE:
GE Healthcare provides transformational medical technologies
and services that are shaping a new age of patient care. Our
expertise in medical imaging and information technologies, medical
diagnostics, patient monitoring systems, performance improvement,
drug discovery, and biopharmaceutical manufacturing technologies
is helping clinicians around the world re-imagine new ways to
predict, diagnose, inform, treat and monitor disease, so patients
can live their lives to the fullest.
GE Healthcare's broad range of products and services enable
healthcare providers to better diagnose and treat cancer, heart
disease, neurological diseases and other conditions earlier. Our
vision for the future is to enable a new "early health" model of
care focused on earlier diagnosis, pre-symptomatic disease
detection and disease prevention. Headquartered in the United
Kingdom, GE Healthcare is a $17 billion unit of General Electric
Company (NYSE: GE). Worldwide, GE Healthcare employs more than
46,000 people committed to serving healthcare professionals and
their patients in more than 100 countries. For more information
about GE Healthcare, visit our website at
www.gehealthcare.com.
Biacore is a trademark of Biacore AB, a company of GE Healthcare.
For further information please contact:
Media Contact for Biacore (GE Healthcare):
Lorna Watson, Account Director
or
Deborah Gaskell, Account Manager
Tel : +44 (0) 20 7268 3237
Email :
Biacore@northbankcommunications.com
Notes
Northbank Communications Ltd -
www.northbankcommunications.com
Northbank Communications, a full service PR and communications
consultancy, focused on serving science-based companies and
organisations, with a strong focus in the life science industry.
Northbank has specialist practices in Corporate, Marketing and
Financial Communications, and an in house design studio.
Northbank Communications Limited was formed through the merger of
Charles Consultants into STMP Marketing Solutions Ltd in November
2002 and operates from offices in London and Congleton (near
Manchester) in the UK, and Munich Germany. The Company employs 31
staff with an annual turnover in excess £2.5m (€3.6m). In 2005
Northbank was finalist in the PR Week Specialist Consultancy of
the Year Award and, in the 2006 PR Week League Table, was ranked
108th overall and 16th in the Healthcare Top 50, achieving one of
the fastest growth rates at 81%. In 2006 it was also finalist in
the CIPR Awards for Excellence in both the corporate and
healthcare categories.
